Mobia Medical says it is a commercial-stage medical device company marketing the Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System for people with chronic ischemic stroke and moderate to severe upper-extremity impairments.

The company described the Vivistim System as an implanted pulse generator and lead that deliver stimulation to the vagus nerve when activated. During Vivistim Therapy, Mobia said short bursts of stimulation are paired with intentional, functional movement to promote neuroplasticity—the brain's ability to reorganize neural pathways after injury.

Mobia said the Vivistim System is the first and only clinically validated, FDA-approved device for this specific population. The company also stated that clinical data have shown meaningful improvements in upper-limb function for treated patients, and that benefits can occur regardless of the time elapsed since the stroke.

The description positions Vivistim as a treatment option for chronic stroke survivors who continue to have significant motor deficits after acute care. All efficacy and approval claims in this article are attributed to Mobia Medical.

Photo credit: www.renaissancecapital.com

Tags: Vivistim, vagus nerve stimulation, stroke recovery, implantable neuromodulation

Topics: Neuromodulation, Vagus nerve & taVNS, Neuroprosthetics & neural implants